We use cookies for analytics and ads to improve your experience. You can accept or decline. See our Privacy Policy.
Unlisted shares are illiquid and carry higher risk than listed securities. Prices are indicative, not live. Read the risk disclosure.

Valuation
Investment Thesis
Amar Remedies Limited is under liquidation with equity value near zero. The company built an Ayurvedic/FMCG business with Rs.26 Cr paid-up capital and multi-location manufacturing but failed to sustain competitively. Equity holders face near-total loss.
Pros
Cons
Business Segments
Ayurvedic Products
Manufacture and trading of Ayurvedic/herbal products including toothpastes, toothbrushes, and wellness items.
Personal Care FMCG
Manufacturing of personal care products: petroleum jelly, talc, soaps, shampoo, lotions, and creams at Daman, Dehradun, Surat plants.
Revenue Model
Amar Remedies Limited is classified in the personal care and skincare FMCG sector, suggesting it historically derived revenue from manufacturing or trading personal care products. Given the negligible share price and absence of public financial data, current revenue generation appears minimal or non-existent.
Detailed Analysis
Growth Plans
Potential revival or acquisition by an active management team
Asset value realisation in case of corporate restructuring
India's booming personal care market provides theoretical opportunity if operations resume
Industry Tailwinds
Potential revival or acquisition by an active management team
Recent Developments
India's personal care and beauty market is projected to grow significantly through 2028, though smaller and inactive companies do not participate in this growth unless operationally active.
2024-01Comparable Companies
HINDUNILVR · ~5,50,000 Cr
Frequently Asked Questions
About Amar Remedies
Amar Remedies Limited is a Mumbai-based personal care and skincare FMCG company incorporated in April 1984. The company was engaged in the manufacture and marketing of personal care products, skincare preparations, and consumer healthcare solutions, operating in India's competitive FMCG personal care segment. Amar Remedies built a portfolio of personal care brands targeting mass-market consumers in India. However, the company has been placed under liquidation proceedings — a critical development that investors must understand. Liquidation under the Insolvency and Bankruptcy Code (IBC) 2016 or earlier frameworks involves the wind-up of company assets to repay creditors in order of statutory priority: secured creditors first, followed by unsecured creditors, with equity shareholders receiving residual value only after all creditor claims are settled. The personal care FMCG sector in India is highly competitive, with large listed players like Hindustan Unilever, Dabur, and Godrej Consumer Products dominating shelf space and distribution networks, making it extremely challenging for smaller manufacturers to sustain profitability long-term. Amar Remedies' liquidation status means equity investors face very high risk of total capital loss. The company's registered CIN is L99999MH1984PLC032687. Any residual equity value depends entirely on the outcome of liquidation proceedings and net asset realisation after creditor repayment. This company represents a cautionary case study in FMCG brand building challenges in India's intensely competitive personal care market.
Key Milestones
Incorporated 1984 in Mumbai, Maharashtra (CIN: L99999MH1984PLC032687)
Common questions about unlisted shares
You buy from and sell to the wisefolio desk — shares route through the desk's demat, money-in before shares-out.
You enquire
· Takes 2 minutesTell us the company and quantity you want. Share your demat details so we can settle directly into your account.
We source & quote
· Typically within 1 business dayOur desk sources the shares and comes back with a firm price and an allocation for the quantity available.
You accept the allocation
· Quote valid for 3 daysReview the price, quantity and total. Accept to lock the allocation. The quote is valid for a short window before it needs re-pricing.
You transfer the funds
· Pay within 2 days of acceptingPay by direct bank transfer to the desk's published account — never to a personal account. We confirm receipt and begin the transfer.
Shares reach your demat
· Usually credited within 2–3 business daysOnce payment is verified, the shares are transferred from the desk's demat into yours, and you receive a transfer confirmation.
A principal desk for unlisted & pre-IPO shares — you transact with us, not a stranger.
You enquire
Takes 2 minutes
We source & quote
Typically within 1 business day
You accept the allocation
Quote valid for 3 days
You transfer the funds
Pay within 2 days of accepting
Shares reach your demat
Usually credited within 2–3 business days
Unlisted shares are illiquid and carry higher risk. Pricing is indicative, not live, and these are private off-market transactions with no exchange settlement guarantee. Read the full risk disclosure.
Asset value realisation in case of corporate restructuring
India's booming personal care market provides theoretical opportunity if operations resume
Industry Headwinds
Company may be effectively dormant or near defunct
No visible brand, distribution, or manufacturing assets confirmed
Risk of regulatory action or MCA strike-off if compliance lapses
CRITICAL: Company is under LIQUIDATION — equity investors face very high risk of total capital loss
Source: IBBI / MCA Public Records
All assets being distributed to creditors; shareholders receive residual only
Source: Media Reports / Public Records
No ongoing business operations
Source: AlphaHub Research
The very low share price of ₹0.01 raises serious concerns about whether the company has any active business operations.
India's personal care sector is dominated by Hindustan Unilever, P&G, ITC, Dabur, Marico, and numerous D2C brands, making it extremely difficult for small players to compete.
Personal care products are regulated by BIS, FDA (Maharashtra), and CDSCO; compliance requirements are significant for smaller manufacturers.
Building a personal care brand in India requires significant marketing investment that may be beyond the company's current capacity.
Negligible share price and unlisted status mean there is effectively no liquidity for investors.
MARICO · ~65,000 Cr
EMAMILTD · ~25,000 Cr
Listed on BSE (532664) and NSE (AMAR); built Ayurvedic/FMCG brand with manufacturing at Daman, Dehradun, Surat
Under liquidation — business failed; delisted from exchanges
Be the first to discuss Amar Remedies — share your research, ask questions, or compare notes with other investors.